FI971536A - Keratinosyytti-kasvutekijän analogeja - Google Patents

Keratinosyytti-kasvutekijän analogeja Download PDF

Info

Publication number
FI971536A
FI971536A FI971536A FI971536A FI971536A FI 971536 A FI971536 A FI 971536A FI 971536 A FI971536 A FI 971536A FI 971536 A FI971536 A FI 971536A FI 971536 A FI971536 A FI 971536A
Authority
FI
Finland
Prior art keywords
growth factor
analogues
keratinocyte growth
keratinocyte
mammals
Prior art date
Application number
FI971536A
Other languages
English (en)
Swedish (sv)
Other versions
FI120040B (fi
FI971536A0 (fi
Inventor
Charles F Morris
William C Kenney
Bao-Lu Chen
Eric W Hsu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI971536A0 publication Critical patent/FI971536A0/fi
Publication of FI971536A publication Critical patent/FI971536A/fi
Application granted granted Critical
Publication of FI120040B publication Critical patent/FI120040B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI971536A 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja FI120040B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US32347594A 1994-10-13 1994-10-13
US32334094A 1994-10-13 1994-10-13
US32347594 1994-10-13
US32334094 1994-10-13
US48782595A 1995-06-07 1995-06-07
US48782595 1995-06-07
IB9500992 1995-10-12
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (3)

Publication Number Publication Date
FI971536A0 FI971536A0 (fi) 1997-04-11
FI971536A true FI971536A (fi) 1997-06-09
FI120040B FI120040B (fi) 2009-06-15

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971420A FI971420A (fi) 1994-10-13 1997-04-04 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI971420A FI971420A (fi) 1994-10-13 1997-04-04 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä

Country Status (23)

Country Link
EP (2) EP0785948B1 (fi)
JP (2) JP4426646B2 (fi)
KR (1) KR100278597B1 (fi)
CN (1) CN1168678A (fi)
AT (2) ATE237633T1 (fi)
AU (1) AU3707795A (fi)
BG (2) BG101392A (fi)
BR (2) BR9509269A (fi)
CA (2) CA2202075C (fi)
CZ (3) CZ297328B6 (fi)
DE (2) DE69535264T2 (fi)
DK (2) DK0785948T3 (fi)
EE (2) EE03975B1 (fi)
ES (2) ES2273338T3 (fi)
FI (2) FI971420A (fi)
HU (2) HUT78050A (fi)
NO (2) NO318761B1 (fi)
NZ (2) NZ505502A (fi)
PL (2) PL320484A1 (fi)
PT (2) PT785948E (fi)
SI (2) SI0804479T1 (fi)
SK (2) SK284534B6 (fi)
WO (2) WO1996011950A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197800T1 (de) 1989-01-31 2000-12-15 Jeffrey S Rubin Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
CZ343795A3 (en) 1993-06-29 1996-07-17 Chiron Corp Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2197926T3 (es) * 1994-10-13 2004-01-16 Amgen Inc. Metodo para purificar factores de crecimiento de queratinocitos.
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
WO1996034017A1 (en) * 1995-04-27 1996-10-31 Coöperatie Suiker Unie U.A. Inulin derivatives
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20010033484A (ko) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
EP1360201A1 (en) * 2001-02-06 2003-11-12 MERCK PATENT GmbH Modified keratinocyte growth factor (kgf) with reduced immunogenicity
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
MXPA04001526A (es) 2001-08-21 2004-05-31 Chiron Corp Composiciones de polipetidos kgf.
US8304387B2 (en) 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
ATE197800T1 (de) * 1989-01-31 2000-12-15 Jeffrey S Rubin Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
CZ285996B6 (cs) * 1993-03-26 1999-12-15 Amgen Inc. Způsob in vitro stimulace produkce nekeratinocytových epithelových buněk a růstový faktor keratinocytů pro léčbu chorob
CZ343795A3 (en) * 1993-06-29 1996-07-17 Chiron Corp Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
JPH09503751A (ja) * 1993-08-02 1997-04-15 プリズム ファーマシュティカルズ，インコーポレイティド 細胞毒性抱合体の単一起源性製剤

Also Published As

Publication number Publication date
BG101392A (en) 1997-10-31
NO971566D0 (no) 1997-04-04
CZ105097A3 (cs) 1998-10-14
ES2196082T3 (es) 2003-12-16
EE9700225A (et) 1998-02-16
NO318761B1 (no) 2005-05-02
ATE237633T1 (de) 2003-05-15
DE69535264T2 (de) 2007-02-01
FI120040B (fi) 2009-06-15
DE69530403D1 (de) 2003-05-22
ES2273338T3 (es) 2007-05-01
BR9509329A (pt) 1997-10-14
SK43197A3 (en) 1999-03-12
NO971568L (no) 1997-06-12
NZ335109A (en) 2000-08-25
DK0804479T3 (da) 2007-01-29
HU226168B1 (en) 2008-05-28
PT804479E (pt) 2007-02-28
NO971568D0 (no) 1997-04-04
PT785948E (pt) 2003-09-30
ATE342278T1 (de) 2006-11-15
AU681546B2 (en) 1997-08-28
SI0785948T1 (en) 2003-08-31
EP0785948B1 (en) 2003-04-16
FI971420A0 (fi) 1997-04-04
JPH10507080A (ja) 1998-07-14
NZ505502A (en) 2005-01-28
EE03975B1 (et) 2003-02-17
CZ98197A3 (cs) 1998-11-11
CZ297329B6 (cs) 2006-11-15
BG101408A (en) 1997-12-30
KR100278597B1 (ko) 2001-01-15
DK0785948T3 (da) 2003-08-04
DE69530403T2 (de) 2003-10-30
PL320484A1 (en) 1997-09-29
CZ297328B6 (cs) 2006-11-15
AU3707795A (en) 1996-05-06
FI971420A (fi) 1997-04-04
JP4216329B2 (ja) 2009-01-28
BG63167B1 (bg) 2001-05-31
WO1996011949A3 (en) 1996-12-12
AU3708395A (en) 1996-05-06
BR9509269A (pt) 1997-12-23
CA2202075C (en) 2003-12-09
JPH10507193A (ja) 1998-07-14
CN1168678A (zh) 1997-12-24
EP0785948A1 (en) 1997-07-30
PL319784A1 (en) 1997-08-18
SK284534B6 (sk) 2005-06-02
CA2201940A1 (en) 1996-04-25
SK45597A3 (en) 1999-02-11
WO1996011950A1 (en) 1996-04-25
CA2202075A1 (en) 1996-04-25
JP4426646B2 (ja) 2010-03-03
EP0804479B1 (en) 2006-10-11
EP0804479A1 (en) 1997-11-05
NO971566L (no) 1997-04-14
HUT78058A (hu) 1999-07-28
SI0804479T1 (sl) 2006-12-31
WO1996011949A2 (en) 1996-04-25
EE9700081A (et) 1997-10-15
HUT78050A (hu) 1999-07-28
FI971536A0 (fi) 1997-04-11
CA2201940C (en) 2009-05-12
DE69535264D1 (de) 2006-11-23
PL182888B1 (pl) 2002-03-29

Similar Documents

Publication Publication Date Title
NO971568D0 (no) Analoger av keratinocyttvekstfaktor
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DK0460062T3 (da) Huperzin A-analoger
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69111768D1 (de) Enzymatische Zusammensetzung zur Bestimmung von Äthanol.
DE59607481D1 (de) Pulvermischung zur Herstellung eines Opakers in Pastenform
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
ATE334672T1 (de) Ginkolide zur hemmung der membranexpression
DK0741746T3 (da) Thymosin alpha 1-analoger
GR1001368B (el) Φαρμακευτικοί φορείς.
ECSP961819A (es) Nuevos inhibidores de farnesil-transferasa, su preparacion y las composiciones farmaceuticas que contienen (caso st 95042)

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOVITRUM AB (PUBL)

Free format text: BIOVITRUM AB (PUBL)

FG Patent granted

Ref document number: 120040

Country of ref document: FI

MM Patent lapsed